Published on August 6th, 2020 📆 | 3367 Views ⚑0
Cytiva licenses Allen Institute’s advanced machine learning technology
Cytiva and the Allen Institute have entered into a license agreement to integrate the Allen Institute’s machine learning technology with Cytiva’s microscopy and image analysis systems to advance the development of cell imaging innovations.
The Allen Institute’s machine learning technology produces fluorescence signal images from transmitted-light microscopy without the use of fluorescent dye reagents or genetically encodable fluorescent proteins. The method provides benefits of both fluorescent imaging and a label-free approach, achieving a clear image of cellular and subcellular structures without the cytotoxic effects and experimental limitations associated with live cell fluorescence microscopy. The technique further enables live cell imaging in three-dimensional (3D) space to generate more physiologically relevant information about biological processes and underlying mechanisms of disease.
Todd Peterson, Ph.D., Chief Scientific Officer of the Allen Institute, says: “This builds on the excellence of our research, teaming up with a leader in imaging and cell analysis systems. Our mission is to pursue complex scientific problems collaboratively with the ultimate goal of translating our research and technologies for impact in healthcare and life science research applications. Our cell and neuroscience teams are pioneering new approaches to visualize cell organization, dynamics, and activities.”
The combination of technologies under the license will enable life scientists and other researchers to harness the power of label-free imaging and to advance 3D cellular analysis through integrated product solutions and leading customer support from Cytiva.
Emmanuel Abate, Vice President, Genomics and Cellular Research at Cytiva, says: “This highly promising technology has the potential to advance microscopy by enabling label-free cell imaging. For scientists to be able to see their samples less invasively would accelerate results in areas such as fundamental human biological research and drug efficacy studies. We look forward to developing it in the future to realize this potential.”
Cytiva is a 3.3 billion USD global life sciences leader with nearly 7,000 employees across 40 sites dedicated to advancing and accelerating therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients.
About the Allen Institute
The Allen Institute is an independent, 501(c)(3) nonprofit research organization founded by philanthropist and visionary, the late Paul G. Allen. The Allen Institute is dedicated to answering some of the biggest questions in bioscience and accelerating research worldwide. The Institute is a recognized leader in large-scale research with a commitment to an open science model. Its research institutes include the Allen Institute for Brain Science, launched in 2003, the Allen Institute for Cell Science, launched in 2014, and the Allen Institute for Immunology, launched in 2018. In 2016, the Allen Institute expanded its reach with the launch of The Paul G. Allen Frontiers Group, which identifies pioneers with new ideas to expand the boundaries of knowledge and make the world better. For more information, visit alleninstitute.org.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.